Evidence map›Paper›PMID 42433228›Full record

ArticleTranslational lung cancer research2026

Is TROP2 ADC ready for EGFR-TKI-resistant NSCLC?

Jiefei Han, Keigo Kobayashi, Rogelio N Velasco, Aaron C Tan

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Jiefei HanCancer Center, Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Keigo KobayashiDepartment of Internal Medicine, Japan Green Vietnam Clinic, Hanoi, Vietnam.
Rogelio N VelascoThoracic Oncology Department, Lung Center of the Philippines, Quezon City, Philippines.
Aaron C TanDivision of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.ORCID https://orcid.org/0000-0001-7292-1114

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

EGFR mutationepidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)non-small cell lung cancer (NSCLC)trophoblast cell-surface antigen 2 antibody-drug conjugate (TROP2 ADC)

Identifiers

PMID42433228
PMCPMC13351904

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.